The DOE’s Genomes to Life program awarded its FY 2004 grants. The winning PIs for the science-based categories are as follows.
Gang Bao, Georgia Tech Research Corporation
Andrew Bradbury, Los Alamos National Laboratory
Carlos Bustamante, Lawrence Berkeley National Laboratory
James Cate, LBNL
Frank Collart, Argonne National Laboratory
JJ Collins, Boston University
Leroy Hood, Institute for Systems Biology
Thomas Huser, Lawrence Livermore National Laboratory
Jay Keasling, LBNL
Martin Keller, Diversa Corp
Stephen Kent, University of Chicago
Charles Lawrence, Wadsworth Center
Kim Lewis, Northeastern University
Huilin Li, Brookhaven National Laboratory
John Moult, University of Maryland Biotechnology Institute
Herbert Sauro, Keck Graduate Institute
Imran Shah, University of Colorado
Mike Shuler, Gene Network Sciences
Richard Smith, Pacific Northwest National Laboratory
Thomas Squier, PNNL
William Studier, Brookhaven National Laboratory
Cliff Unkefer, LANL
Shimon Weiss, University of California, Los Angeles
Xiaoliang Sunney Xie, Harvard University
And in awards news:
Stuart Kim, a developmental biology professor at the Stanford University School of Medicine, won the Ho-Am Prize in medicine and $90,000 for his work with C. elegans. Using arrays, Kim studies groups of genes that have evolved to work together in the worm.
Meanwhile, Andrew Fire won the Heineken Prize for biochemistry and biophysics for discovering RNAi from the Royal Netherlands Academy of Arts and Sciences. The award comes with $150,000.
Geospiza, the Seattle company whose software is used for sequence data management and analysis, hires Rob Arnold as its new president and COO. Todd Smith is still the company’s CEO.
Bill Ladd heads from Spotfire to Genstruct, a company using models to study compounds and find biomarkers, where he will be vice president of discovery systems. Before Spotfire, Ladd worked at Gene Logic and Merck.
Former bioinformatics exec Andrew DePristo, a founding member of GeneData’s US division, has made the transition into drug discovery informatics. After a stint in the preclinical unit of Amgen, DePristo becomes CEO and president of BioReason, a Santa Fe-based software firm targeting the discovery phase.